Nuclear factor kappa-light-chain-enhancer of activated B cells signaling pathway protein (NF-κB signaling pathway protein)

The **NF-κB signaling pathway proteins** comprise a family of transcription factor complexes (not a single molecule) that regulate DNA transcription, cytokine production, cell survival, and inflammation. The most studied members are NF-κB subunits (p65/RelA, c-Rel, RelB, p50, p52), their inhibitors (IκB proteins), and the upstream IκB kinase (IKK) complex. The pathway controls responses to stress, cytokines, pathogens, and cellular injury by inducibly translocating NF-κB dimers to the nucleus and activating genes related to immune response, cell proliferation, and survival. Aberrant or constitutive activation of NF-κB is implicated in cancer, chronic inflammation, autoimmune, neurodegenerative, and cardiovascular diseases, making its components important therapeutic targets—particularly in hematologic malignancies and inflammatory disorders. With both canonical and non-canonical activation routes, this target is highly pleiotropic, complex, and central to cell biology[1][2][3][4][5][6][7][9]. **Note:** - The query “NF-κB signaling pathway proteins” refers to a pathway or *class* of related proteins rather than a single molecular target. This is technically not the canonical form for a drug target, which should refer to specific proteins (e.g., “Nuclear factor NF-kappa-B p65 subunit”, “IκB kinase beta”, etc.). Thus, “is_incorrect: true”; structured information should be mapped to specific subunits or pathway components for drug development or molecular biology purposes.

Other names

NF-kappa B pathway proteinsNF-kappaB signaling proteinsNF-κB complexNF-κB pathway

Inhibition of proteasome-mediated degradation of IκB; Direct inhibition of NF-κB DNA binding or transcriptional activity; Inhibition of IKK complex (IκB kinase); Blockade of upstream cytokine signaling (e.g., TNFα blockers); Suppression of p65/RelA phosphorylation or nuclear translocation